NCT05137262View on ClinicalTrials.gov

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

PHASE2RecruitingINTERVENTIONAL

Enrollment

60

Participants

Timeline

Start Date

October 13, 2021

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions

Urothelial CarcinomaBladder Cancer

Interventions

OTHER

Abiraterone acetate

Given by IV

DRUG

Durvalumab

Given by IV

DRUG

Methotrexate

Given by IV

DRUG

Vinblastine

Given by IV

DRUG

Doxorubicin Hydrochloride

Given by IV

DRUG

Cisplatin

Given by IV

Trial Locations (2)

47405

RECRUITING

Indiana University, Bloomington

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

AstraZeneca

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER